Health care and medicines are among the priorities outlined by the new presidency of the Council of the EU for the first half of 2023.
Sweden, which took over the rotating presidency of the Council of the European Union on 1 January, says it will prioritize a number of health-related initiatives in the first half of the year, including the revision of the EU pharmaceutical legislation, revisions to the regulations on orphan and pediatric medicines, and a new fee structure for the European Medicines Agency.
The presidency said it would also make efforts to keep the issue of antimicrobial resistance “at the top of the...
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.
EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
